Chemical Compound Review:
Dimesnum disodium2-(2- sulfonatoethyldisulfanyl) eth...
Synonyms:
Tavocept, Dimesna, Dimesna [INN], CCRIS 5852, CHEMBL2104318, ...
This record was replaced with 65626.
- Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. Foxall, P.J., Singer, J.M., Hartley, J.M., Neild, G.H., Lapsley, M., Nicholson, J.K., Souhami, R.L. Clin. Cancer Res. (1997)
- Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. el-Yazigi, A., Ernst, P., al-Rawithi, S., Legayada, E., Raines, D.A. Journal of clinical pharmacology. (1997)
- Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Kurowski, V., Wagner, T. Cancer Chemother. Pharmacol. (1997)
- Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Goren, M.P., Houle, J.M., Bush, D.A., Li, J.T., Newman, C.E., Brade, W.P. Clin. Cancer Res. (1998)
- BNP-7787 (BioNumerik/Baxter Oncology/Grelan). Reilly, R.T. IDrugs : the investigational drugs journal. (2004)
- Oral bioavailability of mesna tablets. Stofer-Vogel, B., Cerny, T., Borner, M., Lauterburg, B.H. Cancer Chemother. Pharmacol. (1993)
- Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. James, C.A., Mant, T.G., Rogers, H.J. British journal of clinical pharmacology. (1987)
- Inhibition of rat hepatic microsomal lipid peroxidation by mesna via glutathione. Bast, A., Haenen, G.R., Savenije-Chapel, E.M. Arzneimittel-Forschung. (1987)
- Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna. el-Yazigi, A., Yusuf, A., al-Rawithi, S. Therapeutic drug monitoring. (1995)
- Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Its potential use in the treatment of superficial bladder cancer. Blomgren, H., Hallström, M., Hillgren, H. Anticancer Res. (1991)
- Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Mohrmann, M., Ansorge, S., Schönfeld, B., Brandis, M. Pediatr. Nephrol. (1994)
- The interactions of mesna and dimesna with the sulfate exchange in human red blood cells. Reuther, H., Kohl, M., Wildenauer, D.B. Arzneimittel-Forschung. (1986)
- Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Habs, M.R., Schmähl, D. Cancer (1983)
- Ifosfamide and mesna. Schoenike, S.E., Dana, W.J. Clinical pharmacy. (1990)
- Reduction of dimesna to mesna by the isolated perfused rat liver. Goren, M.P., Hsu, L.C., Li, J.T. Cancer Res. (1998)
- Bioavailability of orally administered mesna. Burkert, H., Lücker, P.W., Wetzelsberger, N., Breuel, H.P. Arzneimittel-Forschung. (1984)